Finch Therapeutics Group Stock News

SOMERVILLE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ: FNCH ), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs, today announced that the U.S. Patent and Trademark Office has issued two new patents covering the company''s FIN-211 enriched consortia microbiome product candidate in development for children with autism spectrum disorder (ASD) and significant gastrointestinal (GI) symptoms. The company''s intellectual property portfolio now includes 59 issued U.S. and foreign patents with more than 130 patent applications pending. The first patent (U.S. Patent No. 11,202,808) covers key technologies involved in addressing ASD and GI symptoms associated with ASD by orally administering a donor-derived microbial community enriched with bacterial isolates from a genus with potential therapeutic applications in ASD.

Finch Therapeutics Group Inc (FNCH) shares closed today 15.8% higher than it did at the end of yesterday. The stock is currently down 49.4% year-to-date, down 49.4% over the past 12 months, and down 49.4% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $11.16 and as low as $8.77 this week.Shares closed 52.0% below its 52-week high and 23.0% above its 52-week low.Trading volume this week was 75.3% lower than the 10-day average and 72.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Finch Therapeutics Group Inc (FNCH) shares closed today 15.8% higher than it did at the end of yesterday. The stock is currently down 49.4% year-to-date, down 49.4% over the past 12 months, and down 49.4% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $11.16 and as low as $8.77 this week.Shares closed 52.0% below its 52-week high and 23.0% above its 52-week low.Trading volume this week was 77.2% lower than the 10-day average and 71.9% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Director Nicholas Haft purchased 63,850 shares of the business’s stock in a transaction on Monday, December 20th. The shares were acquired at an average price of $10.18 per share, for a total transaction of $649,993.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which […]

During the last session, Finch Therapeutics Group Inc. (NASDAQ:FNCH)s traded shares were 0.51 million. At the end of the trading day, the stocks price was $8.95, reflecting an intraday loss of -8.11% or -$0.79. The 52-week high for the FNCH share is $22.50, that puts it down -151.4 from that peak though still a striking Finch Therapeutics Group Inc. (NASDAQ: FNCH) Continues To Thrive In 2021, As Its Stock Is Down -58.02% Year-To-Date Read More »

Finch Therapeutics Group, Inc. (NASDAQ:FNCH)s share price was up 5% during trading on Friday . The company traded as high as $15.58 and last traded at $15.24. Approximately 3,554 shares changed hands during trading, a decline of 96% from the average daily volume of 84,918 shares. The stock had previously closed at $14.51. Separately, Zacks []

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) traded up 5% during mid-day trading on Friday . The stock traded as high as $15.58 and last traded at $15.24. 3,554 shares traded hands during trading, a decline of 96% from the average session volume of 84,918 shares. The stock had previously closed at $14.51. Separately, Zacks Investment Research []

Finch Therapeutics Group, Inc. gapped down before the market opened on Wednesday. The stock had previously closed at $16.62, but opened at $16.24. Finch Therapeutics Group

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) gapped down before the market opened on Wednesday . The stock had previously closed at $16.62, but opened at $16.24. Finch Therapeutics Group shares last traded at $16.33, with a volume of 40 shares traded. Separately, Zacks Investment Research raised shares of Finch Therapeutics Group from a sell rating to [] The post Finch Therapeutics Group (NASDAQ:FNCH) Shares Gap Down to $16.62 appeared first on ETF Daily News .

Finch Therapeutics Group, Inc. (NASDAQ:FNCH)s share price gapped up prior to trading on Wednesday . The stock had previously closed at $13.54, but opened at $14.15. Finch Therapeutics Group shares last traded at $14.47, with a volume of 1,167 shares trading hands. Separately, Zacks Investment Research upgraded Finch Therapeutics Group from a sell rating to []

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) was the recipient of a large drop in short interest in October. As of October 29th, there was short interest totalling 187,900 shares, a drop of 19.1% from the October 14th total of 232,200 shares. Currently, 1.1% of the companys shares are sold short. Based on an average trading volume []

First Midwest Bank Trust Division acquired a new stake in Finch Therapeutics Group, Inc. (NASDAQ:FNCH) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 26,344 shares of the companys stock, valued at approximately $342,000. First Midwest Bank Trust Division owned approximately 0.06% []

Geode Capital Management LLC purchased a new stake in shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 140,521 shares of the companys stock, valued at approximately $1,977,000. A number of other hedge funds have also made []